Desensitization to Brentuximab Vedotin after anaphylaxis in refractory Hodgkin's lymphoma.

Rosalaura V Villarreal González Sandra Nora González-DíazWendy J Santos-FernándezPerla R Colunga-PedrazaAna Laura Varela-ConstantinoDavid Gómez-Almaguer

Published in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2022)

Drug desensitization in 12 or 16 steps allows tolerable administration of brentuximab vedotin after moderate to severe anaphylaxis. The favorable response to treatment of these patients may indicate that desensitization is a viable strategy for patients with relapsed or refractory HL.

Keyphrases

hodgkin lymphoma
end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
diffuse large b cell lymphoma
prognostic factors
peritoneal dialysis
early onset
acute myeloid leukemia
high intensity
emergency department
patient reported outcomes